Art

J-GLOBAL ID：201702278989126528   Reference number：17A0465062

Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis

骨髄線維症の日本人患者の多施設非盲検試験におけるルキソリチニブの安全性と有効性の評価

Author (11)： KOMATSU Norio (Juntendo Univ., Tokyo, JPN) ,  KIRITO Keita (Univ. Yamanashi, Yamanashi, JPN) ,  SHIMODA Kazuya (Univ. Miyazaki, Miyazaki, JPN) ,  ISHIKAWA Takayuki (Kobe City Medical Center General Hospital, Kobe, JPN) ,  OHISHI Kohshi (Mie Univ., Tsu, JPN) ,  OHYASHIKI Kazuma (Tokyo Medical Univ., Tokyo, JPN) ,  TAKAHASHI Naoto (Akita Univ. Graduate School of Medicine, Akita, JPN) ,  OKADA Hikaru (Novartis Pharma KK, Tokyo, JPN) ,  AMAGASAKI Taro (Novartis Pharma KK, Tokyo, JPN) ,  YONEZU Toshio (Novartis Pharma KK, Tokyo, JPN) ,  AKASHI Koichi (Kyushu Univ., Fukuoka, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 105  Issue： 3  Page： 309-317  Publication year： Mar. 2017 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *enzyme inhibitor ,...
Semi thesaurus term： *Janus kinase inhibitor

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0465062&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (2)： Clinical application of enzyme preparations and inhibitor preparations  (GW21020H) ,  Drug therapy(=pharmacotherapy)for hematologic diseases in general  (GK05020P)

Substance index (1)： Ruxolitinib

Reference (35)：

• Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:915-25.
• Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22:905-14.
• Scherber RM, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. Symptomatic burden in myelofibrosis (MF): prospective international assessment in 128 MF patients. J Clin Oncol. 2011;29(suppl) [abstract 6610].
• Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68-76.
• Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233-45.

Terms in the title (9)： 骨髄線維症 ,  日本人 ,  患者 ,  施設 ,  盲 ,  試験 ,  ルキソリチニブ ,  安全性 ,  評価